RU2628537C2 - Лечение нарушений свертываемости крови путем введения рекомбинантного фв - Google Patents

Лечение нарушений свертываемости крови путем введения рекомбинантного фв Download PDF

Info

Publication number
RU2628537C2
RU2628537C2 RU2014100107A RU2014100107A RU2628537C2 RU 2628537 C2 RU2628537 C2 RU 2628537C2 RU 2014100107 A RU2014100107 A RU 2014100107A RU 2014100107 A RU2014100107 A RU 2014100107A RU 2628537 C2 RU2628537 C2 RU 2628537C2
Authority
RU
Russia
Prior art keywords
var
fviii
rfv
patient
multimers
Prior art date
Application number
RU2014100107A
Other languages
English (en)
Russian (ru)
Other versions
RU2014100107A (ru
Inventor
Фридрих ШАЙФЛИНГЕР
Петер Турецек
Брюс ЭВЕНШТАЙН
Винг Йен ВОНГ
Тобиас М. СУИТЕР
Original Assignee
Баксалта Инкорпорейтед
Баксалта Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Баксалта Инкорпорейтед, Баксалта Гмбх filed Critical Баксалта Инкорпорейтед
Publication of RU2014100107A publication Critical patent/RU2014100107A/ru
Application granted granted Critical
Publication of RU2628537C2 publication Critical patent/RU2628537C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2014100107A 2011-06-10 2012-06-11 Лечение нарушений свертываемости крови путем введения рекомбинантного фв RU2628537C2 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161495884P 2011-06-10 2011-06-10
US61/495,884 2011-06-10
US201161511901P 2011-07-26 2011-07-26
US61/511,901 2011-07-26
US201161523790P 2011-08-15 2011-08-15
US61/523,790 2011-08-15
PCT/US2012/041957 WO2012171031A1 (en) 2011-06-10 2012-06-11 Treatment of coagulation disease by administration of recombinant vwf

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2017102679A Division RU2680402C2 (ru) 2011-06-10 2012-06-11 Лечение нарушений свертываемости крови путем введения рекомбинантного фв

Publications (2)

Publication Number Publication Date
RU2014100107A RU2014100107A (ru) 2015-07-20
RU2628537C2 true RU2628537C2 (ru) 2017-08-18

Family

ID=46321496

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2014100107A RU2628537C2 (ru) 2011-06-10 2012-06-11 Лечение нарушений свертываемости крови путем введения рекомбинантного фв
RU2017102679A RU2680402C2 (ru) 2011-06-10 2012-06-11 Лечение нарушений свертываемости крови путем введения рекомбинантного фв

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2017102679A RU2680402C2 (ru) 2011-06-10 2012-06-11 Лечение нарушений свертываемости крови путем введения рекомбинантного фв

Country Status (23)

Country Link
US (3) US9272021B2 (enExample)
EP (3) EP3858375B1 (enExample)
JP (3) JP6347468B2 (enExample)
KR (3) KR101969515B1 (enExample)
CN (3) CN108210889A (enExample)
AR (1) AR086904A1 (enExample)
AU (5) AU2012267458A1 (enExample)
CA (1) CA2838845C (enExample)
DK (3) DK3858375T3 (enExample)
ES (3) ES2976169T3 (enExample)
FI (1) FI3858375T3 (enExample)
HK (1) HK1257436A1 (enExample)
HR (1) HRP20180962T1 (enExample)
HU (1) HUE039317T2 (enExample)
LT (1) LT2717905T (enExample)
MX (2) MX350582B (enExample)
PL (3) PL3858375T3 (enExample)
PT (3) PT3858375T (enExample)
RU (2) RU2628537C2 (enExample)
SG (2) SG10202002591QA (enExample)
SI (1) SI2717905T1 (enExample)
TR (1) TR201808823T4 (enExample)
WO (1) WO2012171031A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101969515B1 (ko) * 2011-06-10 2019-04-16 박스알타 인코퍼레이티드 재조합 vwf의 투여에 의한 응고 질환의 치료
CN102776260B (zh) * 2012-07-26 2015-04-29 上海泰龙生物医药科技有限公司 一种高效表达重组人凝血八因子的方法
ES2657291T3 (es) 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
WO2017180807A1 (en) 2016-04-15 2017-10-19 Baxalta Incorporated Method and apparatus for providing a pharmacokinetic drug dosing regiment
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
FR3034669B1 (fr) * 2015-04-07 2020-02-14 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Nouvelle utilisation du facteur von willebrand
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
DK3648788T3 (da) * 2017-07-07 2024-08-19 Takeda Pharmaceuticals Co Behandling af gastrointestinal blødning hos patienter med svær von willebrand-sygdom ved administration af rekombinant vwf
PT3648787T (pt) * 2017-07-07 2025-01-20 Takeda Pharmaceuticals Co Tratamento de doentes com doença de von willebrand grave submetidos a cirurgia eletiva por administração de vwf recombinante
CN111670202A (zh) 2018-02-06 2020-09-15 埃博灵克斯股份有限公司 以免疫球蛋白单可变结构域治疗ttp初次发作的方法
SG11202009213TA (en) * 2018-03-21 2020-10-29 Baxalta Inc Separation of vwf and vwf propeptide by chromatographic methods
BR112021015068A2 (pt) 2019-02-01 2021-10-05 Takeda Pharmaceutical Company Limited Métodos de tratamento profilático usando vwf recombinante (rvwf)
JP2022547556A (ja) 2019-09-11 2022-11-14 武田薬品工業株式会社 フォン・ヴィレブランド因子と補体ｃ１ｑの複合体に関連する治療法
BR112022015326A2 (pt) * 2020-02-04 2022-10-11 Takeda Pharmaceuticals Co Tratamento de menorragia em pacientes com doença de von willebrand severa por administração de vwf recombinante
WO2022115502A1 (en) * 2020-11-24 2022-06-02 Band Therapeutics, Llc Compositions and methods for treatment of bleeding disorders
WO2024124136A1 (en) * 2022-12-09 2024-06-13 Vega Therapeutics, Inc. Von willebrand disease animal models

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4638028A (en) 1985-04-08 1987-01-20 Goodyear Tire & Rubber Company Rubber polymerases and methods for their production and use
WO1986006096A1 (en) 1985-04-11 1986-10-23 The Children's Medical Center Corporation Von willebrand factor
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
DE4435485C1 (de) * 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
AT403764B (de) * 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
AT406373B (de) * 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
AT405403B (de) * 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
US6531577B1 (en) 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
US6864403B1 (en) 1998-10-15 2005-03-08 E. I. Du Pont De Nemours And Company Plant protein disulfide isomerases
US20040014657A1 (en) * 2001-11-05 2004-01-22 Jan Ohrstrom Use of blood coagulation factor XIII for treating haemophilia A
WO2005012354A1 (en) * 2003-07-31 2005-02-10 Zlb Behring Gmbh Method for extending the half-life of fviii
EP1593388A1 (en) 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
BRPI0519562A2 (pt) * 2004-12-27 2009-01-27 Baxter Int construÇço proteinÁcea, complexo, mÉtodo para prolongar a meia-vida in vivo de fator viii (fviii) ou um derivado biologicamente ativo do mesmo composiÇço farmacÊutica, e, mÉtodo para formar uma construÇço proteinÁcea
SI2522717T1 (sl) 2006-01-04 2014-05-30 Baxter International Inc. Mediji celične kulture brez oligopeptidov
AU2008261261B2 (en) * 2007-06-13 2013-06-27 Csl Behring Gmbh Use of VWF stabilized FVIII preparations and of VWF preparations without FVIII for extravascular administration in the therapy and prophylactic treatment of bleeding disorders
AU2008323768A1 (en) 2007-11-09 2009-05-14 Baxter Healthcare S.A. Modified recombinant Factor VIII and von Willebrand Factor and methods of use
JP2009127455A (ja) 2007-11-20 2009-06-11 Bando Kiko Co Ltd 往復動エンジン
WO2009086400A2 (en) * 2007-12-28 2009-07-09 Baxter International Inc. Recombinant vwf formulations
ES2298096B1 (es) * 2008-01-08 2009-01-01 Grifols, S.A. Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos.
DK2865760T3 (en) * 2008-06-24 2018-01-15 Csl Behring Gmbh Factor VIII, Von Willebrand Factor or complexes thereof with extended in vivo half-life
DK2349314T3 (da) 2008-10-21 2013-05-27 Baxter Int Lyofiliserede præparater af rekombinant VWF
WO2011017414A2 (en) * 2009-08-04 2011-02-10 Baxter International Inc. Transgenic mouse lacking endogenous fviii and vwf - a model of hemophilia a
PT3626736T (pt) 2010-07-08 2025-08-11 Takeda Pharmaceuticals Co Método de produção de fvw recombinante de elevado peso molecular na cultura celular
US20120006800A1 (en) 2010-07-09 2012-01-12 Illinois Tool Works Inc. Weld bead feature communication systems and devices
KR101969515B1 (ko) * 2011-06-10 2019-04-16 박스알타 인코퍼레이티드 재조합 vwf의 투여에 의한 응고 질환의 치료

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FISCHER BE., Recombinant von Willebrand factor: potential therapeutic use.J Thromb Thrombolysis. 1999 Oct;8(3):197-205. MEULIEN P., et al., Processing and characterization of recombinant von Willebrand factor expressed in different cell types using a vaccinia virus vector.Thromb Haemost. 1992 Jan 23;67(1):154-60. FISCHER BE., et al., Structural analysis of recombinant von Willebrand factor produced at industrial scale fermentation of transformed CHO cells co-expressing recombinant furin.FEBS Lett. 1995 Nov 20;375(3):259-62. TURECEK PL., et al., Structure and function of a recombinant von Willebrand factor drug candidate.Semin Thromb Hemost. 2010 Jul;36(5):510-21. doi: 10.1055/s-0030-1255445. Epub 2010 Jul 15. RODEGHIERO F., et al., Treatment of von Willebrand disease.Semin Hematol. 2005 Jan;42(1):29-35. *

Also Published As

Publication number Publication date
US20120316116A1 (en) 2012-12-13
EP2717905A1 (en) 2014-04-16
AU2022201518A1 (en) 2022-03-24
SG10202002591QA (en) 2020-05-28
KR20140039285A (ko) 2014-04-01
RU2017102679A (ru) 2018-12-19
JP2019048892A (ja) 2019-03-28
US9272021B2 (en) 2016-03-01
EP3412305B1 (en) 2021-01-06
AR086904A1 (es) 2014-01-29
JP6347468B2 (ja) 2018-06-27
US20160184403A1 (en) 2016-06-30
CN108210889A (zh) 2018-06-29
RU2017102679A3 (enExample) 2018-12-19
KR20190041032A (ko) 2019-04-19
DK2717905T3 (en) 2018-07-02
CN107412743A (zh) 2017-12-01
CA2838845A1 (en) 2012-12-13
PL3858375T3 (pl) 2024-05-20
KR102319868B1 (ko) 2021-11-01
WO2012171031A1 (en) 2012-12-13
CA2838845C (en) 2019-08-06
HK1257436A1 (zh) 2019-10-18
MX350582B (es) 2017-09-11
BR112013031795A2 (pt) 2016-12-20
DK3858375T3 (da) 2024-04-15
RU2019103386A (ru) 2020-08-07
JP2014516088A (ja) 2014-07-07
PL2717905T3 (pl) 2018-10-31
PL3412305T3 (pl) 2021-05-31
SI2717905T1 (sl) 2018-09-28
CN103732244A (zh) 2014-04-16
MX2013014543A (es) 2014-06-11
KR20200091476A (ko) 2020-07-30
ES2860450T3 (es) 2021-10-05
KR101969515B1 (ko) 2019-04-16
RU2014100107A (ru) 2015-07-20
PT2717905T (pt) 2018-07-02
AU2020200026A1 (en) 2020-01-30
DK3412305T3 (da) 2021-03-01
JP6527114B2 (ja) 2019-06-05
FI3858375T3 (fi) 2024-04-17
PT3858375T (pt) 2024-04-18
MX2020000083A (es) 2020-08-06
ES2976169T3 (es) 2024-07-24
HRP20180962T1 (hr) 2018-10-19
AU2017206235A1 (en) 2017-08-03
EP3858375A1 (en) 2021-08-04
CN107412743B (zh) 2021-07-02
JP2017019788A (ja) 2017-01-26
EP3412305A1 (en) 2018-12-12
AU2017206235B2 (en) 2019-10-17
RU2680402C2 (ru) 2019-02-21
ES2682249T3 (es) 2018-09-19
US20250387455A1 (en) 2025-12-25
AU2012267458A1 (en) 2014-01-09
HUE039317T2 (hu) 2018-12-28
PT3412305T (pt) 2021-01-29
LT2717905T (lt) 2018-10-10
AU2016202299B2 (en) 2017-07-20
EP2717905B1 (en) 2018-05-23
AU2016202299A1 (en) 2016-05-05
NZ618790A (en) 2015-07-31
RU2019103386A3 (enExample) 2022-01-24
AU2022201518B2 (en) 2025-07-03
EP3858375B1 (en) 2024-03-20
SG10201604684WA (en) 2016-07-28
TR201808823T4 (tr) 2018-07-23

Similar Documents

Publication Publication Date Title
US20250387455A1 (en) Treatment of coagulation disease by administration of recombinant vwf
US12016904B2 (en) Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF
US20240009279A1 (en) Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant vwf
RU2787855C2 (ru) Лечение нарушений свертываемости крови путем введения рекомбинантного фактора виллебранда
HK40056758A (en) Treatment of coagulation disease by administration of recombinant vwf
HK40056758B (en) Treatment of coagulation disease by administration of recombinant vwf
HK40001633B (en) Treatment of coagulation disease by administration of recombinant vwf
HK40001633A (en) Treatment of coagulation disease by administration of recombinant vwf
HK1196768B (en) Treatment of coagulation disease by administration of recombinant vwf
HK1196768A (en) Treatment of coagulation disease by administration of recombinant vwf
US20230398188A1 (en) Treatment of menorrhagia in patients with severe von willebrand disease by administration of recombinant vwf
HK40115617A (en) Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf
HK40029176A (en) Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant
HZ9A Changing address for correspondence with an applicant
PC41 Official registration of the transfer of exclusive right

Effective date: 20211028